Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Влияние контрацептива, содержащего эстетрол/дроспиренон на сексуальную функцию женщин репродуктивного возраста
Оразов М.Р., Ермаков В.В., Новгинов Д.С. Влияние контрацептива, содержащего эстетрол/дроспиренон на сексуальную функцию женщин репродуктивного возраста. Гинекология. 2023;25(1):102–105.
DOI: 10.26442/20795696.2023.1.202033
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
DOI: 10.26442/20795696.2023.1.202033
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Orazov MR, Ermakov VV, Novginov DS. Effect of an estetrol/drospirenone contraceptive on sexual function in women of reproductive age. Gynecology. 2023;25(1):102–105. DOI: 10.26442/20795696.2023.1.202033
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Использование гормональной контрацепции широко распространено во всем мире. За долгие годы применения удалось хорошо изучить ее контрацептивную эффективность, а также действие на углеводный обмен, свертывающую систему крови, липидный профиль, печеночные маркеры и другие системы и органы. Однако влияние на сексуальную функцию до настоящего момента остается изученным недостаточно. Долгое время основным эстрогеном в комбинированных оральных контрацептивах оставался этинилэстрадиол, но стремление повысить безопасность привело к разработке нового препарата, содержащего натуральный высокоселективный эстроген эстетрол и уже известный гестаген дроспиренон. В связи с этим актуальным будет изучить влияние нового комбинированного орального контрацептива на сексуальную функцию.
Ключевые слова: эстетрол, дроспиренон, сексуальная функция, сексуальность
Ключевые слова: эстетрол, дроспиренон, сексуальная функция, сексуальность
________________________________________________
The use of hormonal contraception is widespread worldwide. Over the years of use, it has been possible to study its contraceptive effectiveness and its effect on carbohydrate metabolism, blood coagulation, lipid profile, liver function tests, and other systems and organs. However, the effect on sexual function has not been sufficiently studied. For a long time, ethinylestradiol remained the main estrogen in combined oral contraceptives; however, the desire to improve safety led to the development of a new drug containing natural, highly selective estrogen estetrol and the well-known progestogen drospirenone. Therefore, it is relevant to study the effect of the new combined oral contraceptive on sexual function.
Keywords: estetrol, drospirenone, sexual function, sexuality
Полный текст
Список литературы
1. Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11(1):41-7. DOI:10.5812/ijem.4158
2. Gallo MF, Nanda K, Grimes DA, et al. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;2013(8):CD003989. DOI:10.1002/14651858.CD003989.pub5
3. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179(3 Pt 1):577-82.
DOI:10.1016/s0002-9378(98)70047-x
4. Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103(4):213-21. DOI:10.1016/j.contraception.2021.01.001
5. Singer CF, Bennink HJ, Natter C, et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis. 2014;35(11):2447-51. DOI:10.1093/carcin/bgu144
6. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine сontraceptive devices. Am J Obstet Gynecol. 1999;181(5 Pt 1):1263-9.
7. Traish AM, Kim N, Min K, et al. Role of androgens in female genital sexual arousal: receptor expression, structure, and function. Fertil Steril. 2002;77(Suppl. 4):S11-8. DOI:10.1016/s0015-0282(02)02978-3
8. Korenman SG, Sherman BM. Further studies of gonadotropin and estradiol secretion during the preovulatory phase of the human menstrual cycle. J Clin Endocrinol Metab. 1973;36(6):1205-9. DOI:10.1210/jcem-36-6-1205
8. Schindler AE. Non-contraceptive benefits of hormonal contraceptives. Minerva Ginecol. 2010;62(4):319-29.
9. Gaspard U, Taziaux M, Jost M, et al. Estetrol (E4), the next generation hormone therapy (HT) for menopausal symptoms: phase 2b clinical trial results. Maturitas. 2019;124:153. DOI:10.1016/j.maturitas.2019.04.122
10. Gaspard U, Taziaux M, Mawet M, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause. 2020;27(8):848-57. DOI:10.1097/GME.0000000000001561
11. Berry MD, Berry PD. Contemporary treatment of sexual dysfunction: reexamining the biopsychosocial model. J Sex Med. 2013;10(11):2627-43. DOI:10.1111/jsm.12273
12. Tskitishvili E, Pequeux C, Munaut C, et al. Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study. J Endocrinol. 2017;232(1):85-95.
DOI:10.1530/JOE-16-0434
13. Smirnova NF, Fontaine C, Buscato M, et al. The activation function-1 of estrogen receptor alpha prevents arterial neointima development through a direct effect on smooth muscle cells. Circ Res. 2015;117(9):770-8. DOI:10.1161/CIRCRESAHA.115.306416
14. Apter D, Zimmerman Y, Beekman L, et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care. 2017;22(4):260-7. DOI:10.1080/13625187.2017.1336532
15. Cappelletti M, Wallen K. Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens. Horm Behav. 2016;78:178-93. DOI:10.1016/j.yhbeh.2015.11.003
2. Gallo MF, Nanda K, Grimes DA, et al. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;2013(8):CD003989. DOI:10.1002/14651858.CD003989.pub5
3. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179(3 Pt 1):577-82.
DOI:10.1016/s0002-9378(98)70047-x
4. Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103(4):213-21. DOI:10.1016/j.contraception.2021.01.001
5. Singer CF, Bennink HJ, Natter C, et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis. 2014;35(11):2447-51. DOI:10.1093/carcin/bgu144
6. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine сontraceptive devices. Am J Obstet Gynecol. 1999;181(5 Pt 1):1263-9.
7. Traish AM, Kim N, Min K, et al. Role of androgens in female genital sexual arousal: receptor expression, structure, and function. Fertil Steril. 2002;77(Suppl. 4):S11-8. DOI:10.1016/s0015-0282(02)02978-3
8. Korenman SG, Sherman BM. Further studies of gonadotropin and estradiol secretion during the preovulatory phase of the human menstrual cycle. J Clin Endocrinol Metab. 1973;36(6):1205-9. DOI:10.1210/jcem-36-6-1205
8. Schindler AE. Non-contraceptive benefits of hormonal contraceptives. Minerva Ginecol. 2010;62(4):319-29.
9. Gaspard U, Taziaux M, Jost M, et al. Estetrol (E4), the next generation hormone therapy (HT) for menopausal symptoms: phase 2b clinical trial results. Maturitas. 2019;124:153. DOI:10.1016/j.maturitas.2019.04.122
10. Gaspard U, Taziaux M, Mawet M, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause. 2020;27(8):848-57. DOI:10.1097/GME.0000000000001561
11. Berry MD, Berry PD. Contemporary treatment of sexual dysfunction: reexamining the biopsychosocial model. J Sex Med. 2013;10(11):2627-43. DOI:10.1111/jsm.12273
12. Tskitishvili E, Pequeux C, Munaut C, et al. Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study. J Endocrinol. 2017;232(1):85-95.
DOI:10.1530/JOE-16-0434
13. Smirnova NF, Fontaine C, Buscato M, et al. The activation function-1 of estrogen receptor alpha prevents arterial neointima development through a direct effect on smooth muscle cells. Circ Res. 2015;117(9):770-8. DOI:10.1161/CIRCRESAHA.115.306416
14. Apter D, Zimmerman Y, Beekman L, et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care. 2017;22(4):260-7. DOI:10.1080/13625187.2017.1336532
15. Cappelletti M, Wallen K. Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens. Horm Behav. 2016;78:178-93. DOI:10.1016/j.yhbeh.2015.11.003
________________________________________________
1. Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11(1):41-7. DOI:10.5812/ijem.4158
2. Gallo MF, Nanda K, Grimes DA, et al. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;2013(8):CD003989. DOI:10.1002/14651858.CD003989.pub5
3. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179(3 Pt 1):577-82.
DOI:10.1016/s0002-9378(98)70047-x
4. Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103(4):213-21. DOI:10.1016/j.contraception.2021.01.001
5. Singer CF, Bennink HJ, Natter C, et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis. 2014;35(11):2447-51. DOI:10.1093/carcin/bgu144
6. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine сontraceptive devices. Am J Obstet Gynecol. 1999;181(5 Pt 1):1263-9.
7. Traish AM, Kim N, Min K, et al. Role of androgens in female genital sexual arousal: receptor expression, structure, and function. Fertil Steril. 2002;77(Suppl. 4):S11-8. DOI:10.1016/s0015-0282(02)02978-3
8. Korenman SG, Sherman BM. Further studies of gonadotropin and estradiol secretion during the preovulatory phase of the human menstrual cycle. J Clin Endocrinol Metab. 1973;36(6):1205-9. DOI:10.1210/jcem-36-6-1205
8. Schindler AE. Non-contraceptive benefits of hormonal contraceptives. Minerva Ginecol. 2010;62(4):319-29.
9. Gaspard U, Taziaux M, Jost M, et al. Estetrol (E4), the next generation hormone therapy (HT) for menopausal symptoms: phase 2b clinical trial results. Maturitas. 2019;124:153. DOI:10.1016/j.maturitas.2019.04.122
10. Gaspard U, Taziaux M, Mawet M, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause. 2020;27(8):848-57. DOI:10.1097/GME.0000000000001561
11. Berry MD, Berry PD. Contemporary treatment of sexual dysfunction: reexamining the biopsychosocial model. J Sex Med. 2013;10(11):2627-43. DOI:10.1111/jsm.12273
12. Tskitishvili E, Pequeux C, Munaut C, et al. Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study. J Endocrinol. 2017;232(1):85-95.
DOI:10.1530/JOE-16-0434
13. Smirnova NF, Fontaine C, Buscato M, et al. The activation function-1 of estrogen receptor alpha prevents arterial neointima development through a direct effect on smooth muscle cells. Circ Res. 2015;117(9):770-8. DOI:10.1161/CIRCRESAHA.115.306416
14. Apter D, Zimmerman Y, Beekman L, et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care. 2017;22(4):260-7. DOI:10.1080/13625187.2017.1336532
15. Cappelletti M, Wallen K. Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens. Horm Behav. 2016;78:178-93. DOI:10.1016/j.yhbeh.2015.11.003
Авторы
М.Р. Оразов*, В.В. Ермаков, Д.С. Новгинов
ФГАОУ ВО «Российский университет дружбы народов», Москва, Россия
*omekan@mail.ru
ФГАОУ ВО «Российский университет дружбы народов», Москва, Россия
*omekan@mail.ru
________________________________________________
Mekan R. Orazov*, Vasily V. Ermakov, Dmitrii S. Novginov
People’s Friendship University of Russia (RUDN University), Moscow, Russia
*omekan@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.